These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17603881)

  • 1. Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families.
    Filippini S; Blanco A; Fernández-Marmiesse A; Alvarez-Iglesias V; Ruíz-Ponte C; Carracedo A; Vega A
    BMC Med Genet; 2007 Jun; 8():40. PubMed ID: 17603881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
    Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
    Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain).
    Blay P; Santamaría I; Pitiot AS; Luque M; Alvarado MG; Lastra A; Fernández Y; Paredes A; Freije JM; Balbín M
    BMC Cancer; 2013 May; 13():243. PubMed ID: 23683081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin.
    Infante M; Durán M; Acedo A; Pérez-Cabornero L; Sanz DJ; García-González M; Beristain E; Esteban-Cardeñosa E; de la Hoya M; Teulé A; Vega A; Tejada MI; Lastra E; Miner C; Velasco EA
    Clin Genet; 2010 Jan; 77(1):60-9. PubMed ID: 19912264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado.
    Mullineaux LG; Castellano TM; Shaw J; Axell L; Wood ME; Diab S; Klein C; Sitarik M; Deffenbaugh AM; Graw SL
    Cancer; 2003 Aug; 98(3):597-602. PubMed ID: 12879478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1.
    Miramar MD; Calvo MT; Rodriguez A; Antón A; Lorente F; Barrio E; Herrero A; Burriel J; García de Jalón A
    Breast Cancer Res Treat; 2008 Nov; 112(2):353-8. PubMed ID: 18176857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain.
    Llort G; Muñoz CY; Tuser MP; Guillermo IB; Lluch JR; Bale AE; Franco MA
    Hum Mutat; 2002 Mar; 19(3):307. PubMed ID: 11857748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
    Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H
    Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
    Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
    Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM
    Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
    Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
    Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
    de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
    Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
    Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
    Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.
    Bergman A; Flodin A; Engwall Y; Arkblad EL; Berg K; Einbeigi Z; Martinsson T; Wahlström J; Karlsson P; Nordling M
    Fam Cancer; 2005; 4(2):89-96. PubMed ID: 15951958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis.
    Takano EA; Mitchell G; Fox SB; Dobrovic A
    BMC Cancer; 2008 Feb; 8():59. PubMed ID: 18298804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [BRCA1 and BRCA2 mutations in families studied in the program of genetic counselling in cancer of the Valencian community (Spain)].
    Esteban Cardeñosa E; Bolufer Gilabert P; Palanca Suela S; Barragán González E; Oltra Soler S; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Cuevas Cuerda D; Salas Trejo D;
    Med Clin (Barc); 2008 Feb; 130(4):121-6. PubMed ID: 18279628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.